Alligator Bioscience to address immunogenicity with Epibase
Alligator Bioscience AB and AlgoNomics NV announced that they have entered into a collaboration. AlgoNomics will employ its Epibase® platform to complement Alligator Bioscience in the optimization of therapeutic proteins both in their internal projects and in collaborative projects with customers. The collaboration shall allow Alligator to maximally reduce immunogenicity upon optimization of protein therapeutics with their proprietary ssDNA recombination technology FIND®.
"All proteins delivered as biopharmaceuticals could render an immune response. For Alligator it is of great importance to make a responsible risk assessment on any new project. We are therefore grateful to be able to work with AlgoNomics, delivering a state of the art technology, for investigating the theoretical consequence of an immune response", stated Dr. Gun-Britt Fransson, CEO of Alligator Bioscience.
Financial terms and the therapeutic focus of the collaboration were not disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.